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Background: Although there are reports that metronomic cyclophosphamide (CTX) can be immune stimulating, the impact of its
combination with anti-CTLA-4 immunotherapy for the treatment of cancer remains to be evaluated.
Methods: Murine EMT-6/P breast cancer, or its cisplatin or CTX-resistant variants, or CT-26 colon, were implanted into Balb/c
mice. Established tumours were monitored for relative growth following treatment with anti-CTLA-4 antibody alone or in
combination with; (a) metronomic CTX (ldCTX; 20mgkg 1 day 1), b) bolus (150mgkg 1) plus ldCTX, or (c) sequential treatment
with gemcitabine (160mgkg 1 every 3 days).
Results: EMT-6/P tumours responded to anti-CTLA-4 therapy, but this response was less effective when combined with bolus plus
ldCTX. Anti-CTLA-4 could be effectively combined with either ldCTX (without a bolus), or with regimens of either sequential or
concomitant gemcitabine, including in orthotopic EMT-6 tumours, and independently of the schedule of drug administration.
Tumour responses were confirmed with CT-26 tumours but were less pronounced in drug-resistant EMT-6/CTX or EMT-6/DDP
tumour models than in the parent tumour. A number of tumour bearing mice developed spontaneous metastases under
continuous therapy. The majority of cured mice rejected tumour re-challenges.
Conclusions: Metronomic CTX can be combined with anti-CTLA-4 therapy, but this therapy is impaired by concomitant bolus
CTX. Sequential therapy of anti-CTLA-4 followed by gemcitabine is effective in chemotherapy-naive tumours, although tumour
relapses can occur, in some cases accompanied by the development of spontaneous metastases.
In 2010, 14 years after the report of CTLA-4 blockade causing
tumour responses in preclinical models (Mokyr et al, 1998), by
blocking the immune suppressive functions of the CTLA-4 protein,
the anti-CTLA-4 antibody ipilimumab was approved by the FDA
for the treatment of non-resectable or metastatic melanoma
(Hodi et al, 2010). This approval was a pivotal event for cancer
immunotherapy (Pardoll, 2012; Li et al, 2013), a field now enriched
by additional targets such as PD-1, PD-L1, and LAG-3 (Pardoll,
2012; Li et al, 2013; Postow et al, 2015). Despite these successes,
there remain several hurdles to be overcome in the quest for
optimal anti-CTLA-4-based therapy regimens, including minimis-
ing the likelihood of the development of autoimmune toxicity
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(Maker et al, 2006; Li et al, 2013; Gangadhar and Vonderheide,
2014), or devising means to overcome the evolution of drug
resistance to therapy (Tumeh et al, 2014). Currently, there is a
growing interest to improve anti-CTLA-4 therapy by exploiting the
immunostimulating properties of some conventional chemother-
apeutics (Ghiringhelli et al, 2007; Galluzzi et al, 2012).
In this study, we tested whether continuous low-dose (metro-
nomic) chemotherapy, in this case cyclophosphamide (CTX),
which has been reported to act in part by boosting the immune
system (Ghiringhelli et al, 2007; Chen et al, 2010; Pasquier et al,
2010; Andre et al, 2014), could be effectively combined with
CTLA-4 antibody therapy for the treatment of breast cancer in a
preclinical model. Surprisingly, we found that our previously
designed protocol (Shaked et al, 2005), consisting of bolus (high-
dose) CTX injection combined with oral low-dose CTX (ldCTX),
actually hindered the anti-tumour efficacy of anti-CTLA-4 therapy.
Conversely, we noted that metronomic CTX (without an upfront
bolus) can enhance anti-CTLA-4 therapy. Furthermore, even more
impressive tumour responses were obtained using a sequential
regimen of CTLA-4 blockade followed by a previously described
(Francia et al, 2012) metronomic gemcitabine chemotherapy
(160mg kg 1, every 3 days), irrespective of whether it was
evaluated on the parent EMT-6/P tumour or on variants selected
for resistance to cisplatin or to CTX. We also noted that acquired
drug resistance (at least in a subset of mice) was observed with all
therapies evaluated in this study, as was the emergence of
spontaneous metastases. Our results contribute to our under-
standing of the preclinical benefits of chemotherapy regimens in
combination with CTLA-4 blockade (Grosso and Jure-Kunkel,
2013; Jure-Kunkel et al, 2013; Lesterhuis et al, 2013). They also
serve as cautionary notes in that some regimens (e.g. high-dose
CTX) may hinder the beneficial anti-tumour effects of CTLA-4
blockade-based therapies, and that the use of chemotherapy naive
tumours can sometimes produce overly simplistic tumour response
results in preclinical studies.
MATERIALS AND METHODS
Drug preparation. Gemcitabine hydrochloride was purchased from
Selleck Chemicals (Houston, TX, USA) and made up in sterile
phosphate-buffered saline (PBS) immediately before i.p. administra-
tion. CTX was purchased from Sigma-Aldrich (St Louis, MO, USA)
and made up in PBS before i.p. injection or before its addition to
the mice’s drinking water. Metronomic ldCTX was administered at
an estimated 20mgkg 1 day 1 as previously described (Man et al,
2002). Some regimens (termed Bþ ldCTX) included an upfront bolus
dose of CTX, administered on day 1 as a 150mgkg 1 i.p. injection of
CTX (Shaked et al, 2005; Francia et al, 2012).
Anti-CTLA-4 antibody preparation. Anti-mouse CD152
(CTLA-4), FG purified clone 9H10, purchased from Ebioscience
(San Diego, CA, USA), was diluted in PBS immediately before i.p.
injection. Mice were administered 100 mg of the antibody on day 1
of treatment, followed by a 35 mg injection on day 6.
Cell lines. Murine EMT-6/P mammary carcinoma cells (ERþ /
PRþ /HER2þ , B. Teicher–personal communication, and as pre-
viously reported (Chatterjee et al, 1995; Teicher, 1997), and the CTX-
resistant EMT-6/CTX and cisplatin-resistant EMT-6/DDP variants,
were a gift from Beverly Teicher, and they were grown in RPMI
supplemented with 10% fetal bovine serum and 2mM L-glutamine.
Cells were grown in a humidified incubator at 371C and 5% CO2.
In vivo tumour growth assessment. Six-week-old female Balb/c
mice were purchased from Harlan (Indianapolis, IN, USA). Mice
were allowed to acclimatise for 2 weeks before implantation of
tumour cells. To prepare cells for injection, subconfluent plates
were harvested with 1% trypsin-EDTA, and cells were then washed
and resuspended in RPMI at 2 million cells per ml. Two hundred
thousand EMT-6 cells were injected subcutaneously into the flank
of the mice (for CT-26 cells, 1 million cells per mouse were
implanted). Mice were monitored twice weekly for fluctuations in
body weight, and for tumour growth, as measured by Vernier
calipers, and tumour volume was calculated by the formula
(lengthwidth2)/2. Institutional guidelines were followed to
determine when the experimental end points were reached. Results
were also plotted as event-free survival (Kaplan–Meier analysis)
over time, where duration of event-free survival is defined as time
to primary tumour progression beyond 1200mm3 or 415%
weight loss, as per our previous study (du Manoir et al, 2006).
Primary tumour fragments, or established lung metastases, were
isolated from selected killed mice, and used to derive cell cultures
as previously described (Francia et al, 2008, 2009). The orthotopic
implant of EMT-6 and EMT-6DDP cells was carried out as
previously described (Francia et al, 2008, 2009); 100 000 cells in
50 ml were implanted in the inguinal mammary fat pad of mice. All
in vivo procedures and experiments were performed with the
approval of the UTEP IACUC (IACUC reference #: A-201201-1).
Immunohistochemical analysis. Paraffin-embedded EMT-6
tumour sections were cut to 5 m thickness and stained for anti-
CD31 (Abcam 28364) used at a dilution of 1:400, using an antigen
retrieval of citrate buffer pH6. Secondary antibody was goat anti-
rabbit at a dilution of 1:200, using DAB for detection of positive
staining, and counter stained with hematoxylin for contrast.
Statistical analysis. The analysis of variance among groups
(ANOVA), followed by the Student-Newman–Keuls test, was used
to assess the statistical differences of data in vivo. Tumour therapy
results are reported as mean±s.d. Survival curves were plotted by
the method of Kaplan and Meier and were tested for survival
differences using the log-rank test. The level of significance was set
at Po0.05. Statistical analyses were performed using GraphPad
Prism 5.0 (GraphPad Software, San Diego, CA, USA).
RESULTS
Anti-CTLA-4 therapy combined with bolus plus ldCTX. To
evaluate whether metronomic CTX can be effectively combined
with anti-CTLA-4 treatment, we tested a combination regimen on
subcutaneously implanted EMT-6/P tumours (Figures 1A and B).
For the chemotherapy component, we sought to use a Bþ ldCTX
protocol consisting of a bolus CTX (given i.p. on day 1) plus ldCTX
(20mg kg 1day 1, p.o.). Our choice was guided by our previous
study (Shaked et al, 2005) in which the Bþ ldCTX protocol was
shown to more effectively inhibit tumour growth than the sole
ldCTX in the EMT-6/P tumour, as well as in other tumour models.
Mice (n¼ 32) bearing EMT-6/P tumours were treated with saline
(control), Bþ ld CTX, anti-CTLA-4 antibody, or with Bþ ldCTX
plus anti-CTLA-4 antibody. Figure 1B shows the resulting impact
of the therapies on tumour growth. Thus, control treated tumours
grew rapidly, the Bþ ldCTX treatment slowed down tumour
growth, whereas anti-CTLA-4 antibody treatment caused tumour
regressions over a 20 day period – followed by tumour relapses in
the subsequent 15 days. Surprisingly, the Bþ ldCTX plus anti-
CTLA-4 combination therapy did not produce tumour regressions
and, furthermore, it produced a tumour growth rate that was only
marginally slower than was observed with Bþ ldCTX alone. Thus,
Bþ ldCTX significantly hinders the efficacy of anti-CTLA-4
therapy in the EMT-6/P tumour model. This was an unexpected
finding, as we had recently reported that Bþ ldCTX could be
effectively combined with an anti-VEGFR2 antibody (Francia et al,
2008), or with metronomic oral gemcitabine (LY2334737) (Francia
et al, 2009). We also noted that by day 22 the CTLA-4 antibody
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monotherapy resulted in complete tumour regression in two mice,
one of which then began to show tumour regrowth a few days later.
All anti-CTLA-4 treated tumours shrank after the therapy began,
although tumour relapses were eventually observed in 6 out of 7
mice in this group. Therefore, anti-CTLA-4 therapy is effective in
the EMT-6/P tumour model, but its therapeutic efficacy is
significantly hampered by concurrent Bþ ldCTX treatment.
To assess the relative toxicity of the therapies, we monitored
body weights of the mice in the course of the experiment (as per
our previous studies (du Manoir et al, 2006; Francia et al, 2012)).
Figure 1C shows that the treatments that included a Bþ ldCTX
component produced a short-term weight loss (as previously
reported (Shaked et al, 2005)), followed by a gain in weight by the
treated mice. We also plotted the tumour responses as a Kaplan–
Meier plot (Figure 1D), which shows that time to 50% event-free
survival of CTLA-4 antibody treatment was 38 days, a significant
increase compared with 22 days for the control group (P¼ 0.0011
CTLA-4 vs control). Bþ ldCTX had no significant impact on
survival. Figure 1D also shows that one anti-CTLA-4 antibody
treated mouse, which had been bearing a palpable tumour in the
first 2 weeks of this experiment, showed a tumour regression and
remained tumour-free for the whole follow-up period. This mouse
was still tumour-free 400 days later.
Anti-CTLA-4 therapy combined with ldCTX, or with sequential
gemcitabine therapy. We next decided to test whether we could
incorporate other chemotherapy regimens, either in combination
with or subsequent to the anti-CTLA-4 administration. We
reasoned that as high-dose CTX can be immunosuppressive
(Emadi et al, 2009), the bolus CTX dose might impair the immune
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Figure 1. Impact of bolus plus ldCTX combined with anti-CTLA-4 therapy on the growth of EMT-6/P tumours. (A) Schematic of evaluation of anti-
CTLA-4 therapies with metronomic chemotherapy. EMT-6/P breast tumours, or CTX resistant (EMT-6/CTX) or DDP resistant (EMT-6/DDP) tumours
were treated with anti-CTLA-4 antibody (administered on days 1 and 6). Chemotherapy regimens included low-dose metronomic CTX (ldCTX),
bolus plus ldCTX, or gemcitabine. Confirmatory studies were carried out with the murine CT-26 colon tumour. (B) Murine EMT-6/P cells were
implanted s.c. in female Balb/c mice. Therapies began when tumours were 50 mm3; the mice received control (n¼8) saline (i.p.), anti-CTLA-4
(n¼7), bolus plus ldCTX (n¼10), or the combination (n¼ 7) of anti-CTLA-4 together with bolus plus ldCTX. *Po0.05 vs control, #Po0.05 vs CTLA-4
(mean values±s.d.). (C) Mouse weights, as a measure of toxicity of the different treatments. (D) Impact of the different therapies as assessed by
analysis of event-free survival (Kaplan–Meier analysis), where duration of event-free survival is defined as time to primary tumour progression
beyond 1200mm3 or 415% weight loss. Significant event-free survival was observed with anti-CTLA-4 therapy, but this benefit was reduced by
the addition of bolusþ low-dose CTX. The sole survivor, by day 46, in the anti-CTLA-4 therapy group was still alive and tumour-free at day 400
after tumour cell injection. *Po0.05 was taken as statistical indication of difference vs controls and between treated groups.
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stimulating impact of the CTLA-4 blockade – thus negating its
therapeutic benefit. Therefore, we either had to separate time of the
dosing of chemotherapy from that of the anti-CTLA-4 antibody, or
omit the bolus CTX component. We chose to evaluate two
additional strategies. One was to combine anti-CTLA-4 adminis-
tration with ldCTX (i.e. without a bolus). This choice was based on
reports that (in contrast to the high-dose CTX regimens) ldCTX
can stimulate the immune system (Ghiringhelli et al, 2007;
Pasquier et al, 2010; Andre et al, 2014). Furthermore, in our
previous studies, ldCTX effectively inhibited tumour growth
without producing any obvious toxicity (Man et al, 2002; Francia
et al, 2009). The second strategy involved the incorporation of a
metronomic regimen of 160mg kg 1 gemcitabine given every 3
days, as we recently observed that it can produce remarkable
tumour responses in a preclinical breast cancer model (Francia
et al, 2012). However, to avoid the possibility that gemcitabine
might impair the therapeutic effect of the CTLA-4 blockade, we
decided to administer the two drugs sequentially (i.e. after tumours
began to regress following the anti-CTLA-4 treatment). To
evaluate these alternative therapies, we implanted EMT-6/P
tumours into 43 mice, which were subsequently divided into seven
groups. Therapies began when all mice had established tumours
and when the average tumour volume wasB50mm3. We noted no
or minimal impact of tumour growth, compared with controls, in
the groups treated with ldCTX (Figure 2A). We also noted that
anti-CTLA-4 therapy led to a significant (initial) tumour regression
in the first 2 weeks after therapy started, followed by tumour
relapses. The combination of anti-CTLA-4 plus ldCTX (both
co-administered from day 6 onwards) produced a greater
inhibition of tumour growth that was observed with the anti-
CTLA-4 monotherapy, although the results did not reach a
statistical significance. The group treated with a single dose of
gemcitabine unexpectedly showed weight loss in the days following
treatment, and therefore this treatment was interrupted; the
treatment caused initial inhibition of tumour growth, followed by
tumour regrowth (Figure 2A), and a recovery of mouse body
weight (Figure 2B). One group (treated with anti-CTLA-4 then
Gem) initially received anti-CTLA-4 antibody, which again
produced a tumour regression that lasted 2 weeks, followed by a
tumour relapse (Figure 2A). For this group, as soon as tumours
started to relapse (i.e. around day 21), the second-line therapy of
gemcitabine was administered. In this group, we did not observe
any weight loss after gemcitabine injection, and therefore
gemcitabine treatment was continued. At the onset of the
second-line gemcitabine therapy on day 21, all mice in this group
had visible tumours and an average tumour volume of 145mm3.
Gemcitabine administration caused tumours to regress again, and
by day 36 only two out of the six mice had any palpable tumours.
These two mice eventually showed tumour re-growths, whilst
under continuous gemcitabine therapy (Figure 2C). The remaining
four mice showed significant (Po0.05) and complete tumour
regression and are still tumour-free over 400 days later.
With regard to the relative toxicity of the tested therapies, other
than the single gemcitabine treatment group as noted above, no
significant changes in mouse weight were observed compared with
controls (Figure 2B). As noted in the subsequent studies (detailed
below), we infrequently observed toxicity following gemcitabine
injection, and this was typically resolved by allowing the mice a
break from the treatment, as in our previous study (Tang et al,
2010). No toxicity was observed in the CTLA-4 then gemcitabine
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Figure 2. Effective combination of chemotherapy with anti-CTLA-4 therapy for the inhibition of the growth of EMT-6/P tumours. (A) Murine
EMT-6/P cells were implanted s.c. in female Balb/c mice. Therapies began when tumours were 50mm3; the mice received control saline
(i.p.; n¼7), anti-CTLA-4 (n¼ 6), bolus plus ldCTX (n¼ 7), a single dose of gemcitabine (160mgkg 1; n¼ 5), ldCTX (ldCTX; n¼6), or the
combination of anti-CTLA-4 plus ldCTX (n¼ 6). One additional group received anti-CTLA-4 therapy as a first line treatment and then (when the
tumours began to relapse around day 21) a second-line therapy consisting of gemcitabine (160mgkg 1 every 3 days, i.p.; n¼6), starting on day
21. *Po0.05 vs control, #Po0.05 vs CTLA-4 then gem (mean values±s.d.). (B) Mouse weights, as a measure of toxicity of the different treatments.
(C) Kaplan–Meier plot of event-free survival, where duration of event-free survival is defined as time to primary tumour progression beyond
1200mm3 or 415% weight loss. *Po0.05 was taken as statistical indication of difference vs controls and between treated groups. Significant
event-free survival was observed with anti-CTLA-4 therapy, and this benefit could be improved by the combination of anti-CTLA-4 therapy plus
metronomic CTX, or by the sequential regimen using a first line of anti-CTLA-4 followed by gemcitabine chemotherapy on relapsing tumours.
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group after the gemcitabine treatment started, and treatment
continued for another 30 days without producing any obvious
toxicity.
We also performed a Kaplan–Meier analysis (Figure 2C), which
showed the observed event-free survival in four out of six mice in
the CTLA-4 then gemcitabine group. We also noted long term
event-free survival (4400 days) in one out of six mice for both the
CTLA-4 monotherapy group and for the CTLA-4 plus ldCTX
group.
With regards to the CTLA-4 then gemcitabine treated group, we
note that the two mice with visible tumours after day 36 eventually
showed tumour relapses, and that one of these mice developed
advanced lung metastases (while under gemcitabine therapy),
and was sacrificed on day 107 (Supplementary Figure 1 and
Supplementary Table 1). These results show that although the anti-
CTLA-4 then gemcitabine therapy is highly effective, tumour drug
resistance eventually can develop in a subset of mice, and that
metastatic disease (to the lungs) can develop, under therapy, in this
tumour model.
Anti-CTLA-4-based therapies in EMT-6 tumours resistant to
CTX. To evaluate the impact of selected CTLA-4-based therapies
on drug-resistant tumours, we implanted 50 mice with the EMT-6/
CTX tumour, a population previously selected for in vivo resistance
to CTX (Teicher et al, 1990). We noted a similar relative response
to the different therapies as we had noted with the parental
EMT-6/P tumour, although therapeutic benefit was reduced in the
EMT-6/CTX drug-resistant model (Figure 3A). The initial
administration of gemcitabine, either on its own or following
CTLA-4 therapy, did not produce any immediate toxicity, and was
continued. Only after more than five cycles of gemcitabine did we
see some drop in mouse weights (particularly with gemcitabine
alone), but this was readily resolved by adopting our previously
reported strategy (Tang et al, 2010) of giving the mice short breaks
in therapy (as shown by the arrows in Figures 3A and B).
Gemcitabine monotherapy initially produced a significant
(Po0.05) impact on tumour growth, but eventually all mice
developed drug resistance (while under continuous therapy) as
shown in Figure 3C. Similarly, CTLA-4 therapy followed by
gemcitabine treatment resulted in some tumours initially regres-
sing, although in a number of mice drug resistance later developed
under continuous gemcitabine therapy. 40% of mice in the CTLA-
4 followed by gemcitabine therapy showed cures, whereas others
developed drug resistance by day 80. The mice that did not develop
resistance by day 80 were alive past day 200 – with no sign of
tumour growth after cessation of therapy. Thus although in drug-
resistant tumours (i.e. EMT-6-CTX) the CTLA-4-based therapies
are less effective and drug resistance can readily emerge, we still
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Figure 3. Combination of chemotherapy with anti-CTLA-4 therapy for the inhibition of the growth of EMT-6/CTX tumours, including
gemcitabine administration (as indicated by the green and orange arrows). (A) Murine EMT-6/CTX cells were implanted s.c. in female Balb/c
mice. Therapies began when tumours were 50mm3; the mice received control saline (i.p.; n¼8), anti-CTLA-4 (n¼ 7), gemcitabine (160mgkg 1
every 3 days, i.p.; n¼5), bolus plus ldCTX (n¼8), metronomic CTX (n¼7), or the combination of anti-CTLA-4 plus metronomic CTX (n¼8). One
additional group received anti-CTLA-4 therapy as a first line treatment and then a second-line therapy consisting of gemcitabine (160mgkg 1
every 3 days, i.p.; n¼7). *Po0.05 vs control (on days 13, 15, and 17, Po0.05 for gemcitabine, CTLA-4þ ldCTX and Bþ ldCTX; whereas for
CTLA-4 and for CTLA-4 then gem, Po0.05 on days 15 and 17), #Po0.05 vs CTLA-4 then gem (mean values±s.d.). (B) Mouse weights, as a
measure of toxicity of the different treatments (y indicates significant toxicity caused by gemcitabine treatment). (C) Kaplan–Meier plot of event-
free survival, where duration of event-free survival is defined as time to primary tumour progression beyond 1200mm3 or 415% weight loss.
*Po0.05 was taken as statistical indication of difference vs controls and between treated groups. Significant event-free survival was observed with
anti-CTLA-4 therapy, and this benefit could be improved by the sequential regimen using a first line of anti-CTLA-4 followed by gemcitabine
chemotherapy on relapsing tumours. No significant difference was observed between anti-CTLA-4 therapy and combination of anti-CTLA-4
therapy plus metronomic CTX.
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noted a number of ‘cures’ with the CTLA-4-based therapies.
Furthermore, for those tumours that showed the development of
drug resistance, CTLA-4 followed by gemcitabine therapy was the
most effective regimen in delaying tumour regrowth although
not statistically significant if compared with gemcitabine alone
(with the exception of the volume measurement at day 50). Instead,
Figure 3C shows that CTLA-4 then gemcitabine treatment
produced a significantly longer survival compared with controls
(P¼ 0.0002) and other treatments such as Bþ ldCTX (P¼ 0.0003)
or gemcitabine alone (P¼ 0.0236). In contrast, metronomic CTX
plus anti-CTLA-4 did not produce a significantly different
response when compared with anti-CTLA-4 therapy alone.
Anti-CTLA-4-based therapies in EMT-6 tumours resistant to
cisplatin. Our results with the EMT-6/CTX model suggested that
although metronomic CTX can be combined with CTLA-4 blockade,
this regimen is not effective in tumours resistant to CTX. To further
explore how drug-resistant tumours respond to CTLA-4-based
therapies, we evaluated their impact on the EMT-6/DDP model, a
variant selected for resistance to cisplatin treatment in vivo (Teicher
et al, 1990). Figure 4A shows that in this drug-resistant tumour
the CTLA-4 plus ldCTX had a greater anti-tumour effect than
CTLA-4, although the difference was not statistically significant.
The gemcitabine monotherapy was initially very effective, and did not
produce toxicity, although all the mice eventually had tumours that
became resistant to this therapy. The greatest anti-tumour effect was
obtained with CTLA-4 followed by gemcitabine, and in this case
we also did not see significant toxicity with the gemcitabine
therapy (Figures 4A and B). Moreover, also in terms of survival
this combination determined a significant (P¼ 0.0018) benefit if
compared with controls or CTLA-4 alone (P¼ 0.0010) (Figure 4C).
In this aggressive EMT-6/DDP model, we did not observe any CTLA-
4 blockade-induced tumour regression, but only a growth delay.
Consequently the second-line gemcitabine therapy started on day 19,
when the data showed that tumours were no longer growth delayed.
These results confirm the effectiveness of combining some
chemotherapy regimens with anti-CTLA-4 therapy, but they also
indicate that the use of chemotherapy naive tumours (e.g. EMT-6/P)
may produce overly optimistic results on the therapeutic benefit of
some combination therapies.
CTLA-4 therapies on orthotopically implanted tumours. Our
results raised a number of questions: (1) Are the tumour responses
also observable in orthotopic tumours?, (2) can the results
be replicated in a tumour model other than the EMT-6, and
(3) is metronomic chemotherapy more effective when given in
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conjunction with anti-CTLA-4, or should it be given sequentially? To
answer the first question, we implanted EMT-6/P and EMT-6/DDP in
the inguinal mammary fat pad, as previously described (Francia et al,
2008, 2009), and then evaluated our most effective therapy (i.e. anti-
CTLA-4 with sequential gemcitabine). Anti-CTLA-4 produced a
tumour growth delay in both models (Figures 5A and B), and the
sequential addition of gemcitabine produced an initial tumour
regression. Owing to the rapid growth of these orthotopic tumours,
it was difficult to compare gemcitabine alone with anti-CTLA followed
by gemcitabine, as the latter sequential treatment started with larger
tumours (i.e. 400mm3) following the end of CTLA-4 administration
(i.e. around day 16 in both Figures 5A and B). Nonetheless, in spite of
this challenge, the response obtained with the EMT-6/P and EMT-6/
DDP models was consistent with our results with these tumours when
grown subcutaneously (Figures 3 and 5). Thus, EMT-6/P respond to
CTLA-4 with sequential gemcitabine therapy, but the drug-resistant
EMT-6/DDP are less responsive to this regimen.
Evaluation of therapies in CT-26 tumours. Our preliminary studies
with the murine CT-26 colon tumour (Supplementary Figures 2 and
3) showed that it responded to CTLA-4 therapies, and to gemcitabine.
We therefore implanted CT-26 cells s.c. in Balb/c mice and evaluated
our most effective combination therapy from our experiments with
the EMT-6/P tumour (Figure 2). As shown in Figure 6, whereas
CTLA-4 or gemcitabine monotherapies inhibited CT-26 tumour
growth, the administration of CTLA-4 followed by metronomic
gemcitabine led to tumour regression.
Evaluation of combination vs sequential treatment. To test
whether gemcitabine is more effective than CTX as a drug partner
for CTLA-4 therapies, and whether sequential chemotherapy
is better than combination therapy, we implanted the highly
responsive EMT-6/P tumour and evaluated different CTLA-4-
based therapies. As shown in Figure 7, anti-CTLA-4 is more
effective when it is combined with gemcitabine – given either
sequentially, or concomitantly – than when it is combined with
metronomic CTX (Figure 7). Therefore, our data suggest that the
drug partner for CTLA-4 (i.e. gemcitabine) is more critical for
effective anti-tumour response than is the schedule by which the
drugs are given.
Intratumoral CD31 staining and assessment of immune
memory. To evaluate the impact of the different therapies on
intratumoral blood vessel distribution (as a relative measure of
angiogenic activity within treated tumours), we reassessed the data
in Figures 1 and 2, and noted that maximal therapeutic response
was noted 9–12 days after treatment started. This, taking note of
the data in Figure 2, we implanted EMT-6 tumours s.c., and then
administered the different therapies (using 5–7 mice per group,
following the same regimens shown in Figure 2) when tumours
reached an average size of 200mm3. Thereafter tumours were
measured daily, and the mice were sacrificed and the tumours
excised after 7–12 days of therapy. At this termination point,
tumours were 400–500mm3 in size. Excised tumours were paraffin
embedded and then evaluated for CD31 staining (Figure 8A).
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Analysis of the results (Figure 8B) showed that, as expected, ldCTX
caused a relative reduction in intratumoral CD31 staining
compared with controls – but no significant differences in staining
were observed in tumours that received CTLA-4-based therapies.
In a number of our experiments (shown in Figures 2–5), a few
mice were cured by anti-CTLA-4 or combination therapies, and a
number of mice survived for more than 500 days (some of the mice
died of old age, after 400 or more days, without evidence of tumour
regrowth). These results provided us with a very small pool of
animals that had been cured of the implanted tumour, and
these were used in tumour re-challenge experiments, where each
mouse was given a second s.c. injection of originally implanted
tumour cell line. Our results (Supplementary Figures 4–6 and
Supplementary Table 2) show that in 11/14 cases, the mice rejected
the re-implanted tumour (injected between 60 and 500 days after
the first tumour implant), suggesting that CTLA-4 combination
therapies can produce tumour responses that are accompanied
by the establishment of immune memory. These observations
are consistent with previously published data on anti-CTLA-4
therapies (Jure-Kunkel et al, 2013).
DISCUSSION
A number of immunotherapy approaches have in recent years
translated into significant increased survival in patients with
cancers such as melanoma. For example, targeting CTLA-4 using
ipilimumab is used for the treatment of non-resectable metastatic
melanoma, and clinical trials are ongoing to test its use for the
treatment of other malignancies, including lung cancer, prostate
cancer, and breast cancer (www.clinicaltrials.gov). Furthermore, a
number of active clinical trials are evaluating different combina-
tions of chemotherapy and ipilimumab in melanomas and other
types of cancer (Postow et al, 2015).
We previously reported extensively on experimental therapeutic
studies of metronomic chemotherapy (Man et al, 2002;
Emmenegger et al, 2007, 2011; Francia et al, 2009, 2012;
Tang et al, 2010; Bocci et al, 2012; Hackl et al, 2013; Chow et al,
2014), including the use of metronomic CTX chemotherapy
(Kerbel and Kamen, 2004) with an upfront bolus CTX dose
(Shaked et al, 2005), and the use of sequential chemotherapy
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regimens, as well as second-line therapies (du Manoir et al, 2006;
Chow et al, 2014). The proposed mechanisms of action for
metronomic chemotherapy are many (Bocci et al, 2003; Kerbel and
Kamen, 2004; Pasquier et al, 2010; Bocci et al, 2012; Francia et al,
2012), and they include inhibition of angiogenesis and inhibition of
cancer stem cell growth. They also include activation of the
immune system (Ghiringhelli et al, 2007; Pasquier et al, 2010;
Andre et al, 2014). With regards to the latter, this has been
documented for CTX (and for gemcitabine (Lesterhuis et al,
2013)), and it remains to be determined the extent to which
metronomic dosing of other clinically used chemotherapy drugs
can also activate the immune system.
As ipilimumab therapy is directed at immune activation
(via inhibition of suppressor T-cells), and as combinations of
ipilimumab with chemotherapy are being evaluated clinically, we
sought to investigate whether the immune activation activity of
CTLA-4 blocking could be augmented by the addition of
metronomic CTX. Such combinations could provide data relevant
to current clinical trials, such as the recently reported phase III
trials of metronomic chemotherapy (Simkens et al, 2015; Colleoni
et al, 2016). For example, treatment with CTLA-4 might be
followed by a metronomic maintenance treatment, given the
clinical low toxicity profile of metronomic chemotherapy (Kerbel
and Kamen, 2004; Pasquier et al, 2010), as we have also reported
(Lien et al, 2013; Orlandi et al, 2013; Derosa et al, 2014). We
sought to use what, according to our previous studies, was the most
effective metronomic-type CTX regimen; a protocol (Shaked et al,
2005) involving an upfront bolus (B) CTX dose, immediately
followed by a metronomic CTX (ldCTX) regimen of adding CTX
to the mice’s drinking water (Man et al, 2002). To our surprise, this
Bþ ldCTX approach actually caused a less effective tumour
response than the anti-CTLA-4 monotherapy alone. Therefore,
our results serve as a cautionary note against the use of a bolus plus
metronomic CTX component in therapies involving a CTLA-4
blockade.
We previously reported that bolus plus metronomic CTX
could be improved by the addition of a targeting agent such as the
anti-VEGFR2 antibody DC101 (Francia et al, 2008), or by the
addition of metronomic LY2334737, an oral gemcitabine pro-drug
(Francia et al, 2012). However, we had hitherto not yet observed
that the bolus plus metronomic CTX could hinder the anti-tumour
efficacy of a targeted therapy, or of other anti-tumour strategies.
One possible interpretation of our results is that the bolus (high-
dose) CTX, in our Bþ ldCTX regimen, is immunosuppressive thus
blunting the therapeutic effect of anti-CTLA-4. We consequently
sought to test two alternative strategies. One was to omit the bolus
upfront CTX dose, and administer anti-CTLA-4 together with
metronomic CTX. The second was to adopt gemcitabine
chemotherapy (160mg kg 1 every 3 days) as we recently reported
that it produces notable responses in a LM2-4 preclinical breast
cancer model (Francia et al, 2012). However, to avoid the
possibility that gemcitabine administration would impair the
CTLA-4 blocking strategy, we chose to separate its administration
from that of the CTLA-4 antibody. Thus, we either combined
a CTLA-4 with a sequential gemcitabine therapy, or we
co-administered CTLA-4 antibody together with metronomic
CTX. The results we obtained suggest that both strategies can
improve a CTLA-4 monotherapy regimen, with the sequential
gemcitabine therapy generating the more potent anti-tumour
responses in the EMT-6/P model. Similar results were obtained
with the CTX-resistant EMT-6/CTX and cisplatin-resistant EMT-
6/DDP models, although in the drug-resistant models the benefits
of these therapies were less evident and drug resistance to
gemcitabine readily arose. The reduced sensitivity of the EMT-6/
DDP tumour to CTLA-4 with sequential gemcitabine therapy,
compared with the response seen with the parent EMT-6/P
tumour, was confirmed in orthotopically implanted tumours. In
addition, the effectiveness of the same sequential therapy was
confirmed in CT-26 tumours. Furthermore, our data show that the
effectiveness of CTLA-4 with sequential gemcitabine does not
impact the relative intratumoral CD31 staining in EMT-6/P
tumours, and we subsequently found that gemcitabine is equally
effective irrespective of whether it is given sequentially or
concomitantly with anti-CLTA-4 therapy. The intratumoral
CD31-staining data we obtained are consistent with our previous
study (Francia et al, 2012) showing that metronomic gemcitabine
(and metronomic oral gemcitabine pro-drug) can inhibit tumour
growth without impacting systemic angiogenesis. Overall, there are
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five aspects of this work that deserve to be highlighted: (1) bolus
plus low-dose CTX can impair the antitumor efficacy of anti-
CTLA-4 therapy. (2) Metronomic CTX, or metronomic gemcita-
bine, can effectively be combined with anti-CTLA-4 therapy and,
(3) such combination therapies are also active against drug-
resistant tumours (e.g. EMT-6/CTX and EMT-6/DDP). (4) The
efficacy of chemotherapy plus anti-CTLA-4 is not dependent on
the schedule of drug administration, and (5) produces anti-tumour
effect in the absence of significant changes in intratumoral blood
vessel distribution. Our results also suggest that alternative anti-
tumour mechanisms are involved, including (as we previously
suggested (Francia et al, 2012)), the direct targeting of tumour cells
by the frequent (i.e. every 3 days) gemcitabine administration.
Future studies will have to determine whether anti-CTLA-4
therapy impairs the induction of thromobospondin-1 by metro-
nomic chemotherapy (Bocci et al, 2003), and determine if such
combinations can activate the immune system. That could be
assessed by testing whether such therapies result in an increase in
intratumoral CD4 and CD8 staining, which would be consistent
with studies showing activation of the immune system by
metronomic chemotherapy (Ghiringhelli et al, 2007).
These results may be of interest to clinicians and translational
researchers that are studying means of improving anti-CLTA-4
therapy, and they also caution that these therapies may be less
effective in drug-resistant tumours. We did encounter a few cases
of toxicity associated with gemcitabine administration, which may
have been a consequence of tumour lysis syndrome, which has
been reported by a few studies for this drug (Lin et al, 2007).
However, in our experience, these problems were easily overcome
by giving the mice short drug-free breaks, a procedure that is not
infrequent with cancer patients, (Llovet et al, 2008), as we
previously reported with metronomic sorafenib in a preclinical
model (Tang et al, 2010).
We had expected that Bþ ldCTX would increase the efficacy of
anti-CTLA-4 therapy – but our results proved otherwise. None-
theless, we also observed that some chemotherapy regimens can be
effectively combined with anti-CTLA-4 therapy. Our results are in
agreement with studies by other groups; such as those by Mokyr
et al (1998), who showed that low-dose melphalan can be
effectively combined with anti-CTLA-4 therapy, and of Lesterhuis
et al (2013), who recently reported that anti-CTLA-4 can be co-
administered with gemcitabine to produce significant anti-tumour
responses. Similarly, Jure-Kunkel et al (2013) recently showed the
effective combination of anti-CTLA-4 plus chemotherapy, invol-
ving the injection of the anti-CTLA-4 antibody one day after the
administration of chemotherapy (including gemcitabine). We had
not initially considered such a regimen, because of our disappoint-
ing results with the Bþ ldCTX. In contrast to the aforementioned
studies, one evident difference in our work is the inclusion of
tumour variants selected in vivo for resistance to alkylating agents
(Teicher et al, 1990), which we have previously used to study
mechanisms of tumour drug resistance (Francia et al, 2004). These
variants can be used to model the clinical situation where patients
are eligible for immunotherapy following tumour relapses under
standard chemotherapy regimens. In such cases, the response to
immunotherapy might differ from that of chemotherapy-naive
tumours. In that regard, the EMT-6/CTX and EMT-6/DDP
variants produced less pronounced therapeutic benefits than the
EMT-6/P tumour, a result that highlights how the sole use of
chemotherapy naive tumours may exaggerate the potential
preclinical benefit of a therapy. That is analogous to our
observation that preclinical primary tumour models may in some
cases exaggerate the impact of a therapy on the more clinically
relevant metastatic disease (Francia et al, 2011). In that respect, a
number of mice in this study eventually succumbed to spontaneous
metastases. Overall, results obtained in this study show that
although chemotherapy can augment the impact of anti-CTLA-4
therapy, caution is necessary in the design of such combinations, as
some may be counterproductive.
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